82 FR 36151 - National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 148 (August 3, 2017)

Page Range		36151-36151
FR Document		2017-16314

Federal Register, Volume 82 Issue 148 (Thursday, August 3, 2017)

[Federal Register Volume 82, Number 148 (Thursday, August 3, 2017)]
[Notices]
[Page 36151]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-16314]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel NIAID Clinical Trial Implementation 
Grant (R01).
    Date: August 28, 2017.
    Time: 12:00 p.m. to 2:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 5601 Fishers Lane, 
Rockville, MD 20892 (Telephone Conference Call).
    Contact Person: Kelly Y. Poe, Ph.D., Scientific Review Program, 
Division of Extramural Activities, Room 3F40B National Institutes of 
Health, NIAID, 5601 Fishers Lane, MSC 9823, Bethesda, MD 20892-9823, 
(240) 669-5036, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: July 28, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-16314 Filed 8-2-17; 8:45 am]
BILLING CODE 4140-01-P

Federal Register / Vol. 82, No. 148 / Thursday, August 3, 2017 / Notices 36151

corrections in the scientific record noted working with PHS; however, if within DEPARTMENT OF HEALTH AND
below, and additional analysis five (5) years of the effective date of the HUMAN SERVICES
conducted by ORI in its oversight Agreement, the Respondent receives or
review, ORI found that Dr. Nasser applies for PHS support, the National Institutes of Health
Chegini, retired as a Professor in the Respondent agreed to have his research
Department of Obstetrics and supervised for a period of five (5) years National Institute of Allergy and
Gynecology, UF, engaged in research from the date of his employment in a Infectious Diseases; Notice of Closed
misconduct in research supported by position in which he receives or applies Meeting
National Institute of Child Health and for PHS support and agreed to notify his Pursuant to section 10(d) of the
Human Development (NICHD), National employer(s)/institution(s) of the terms of Federal Advisory Committee Act, as
Institutes of Health (NIH), grant 2 R01 this supervision; Respondent agreed amended, notice is hereby given of the
HD037432. that prior to the submission of an following meeting.
ORI acknowledges that the following application for PHS support for a The meeting will be closed to the
papers were retracted as a result of the research project on which the public in accordance with the
institution’s investigation: Respondent’s participation is proposed provisions set forth in sections
1. J Clin Endocrinol Metab 88(10):4967–4976, and prior to Respondent’s participation 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
2003. Retraction in: J Clin Endocrinol in any capacity on PHS-supported as amended. The grant applications and
Metab 100(1):318, 2015 Jan. research, Respondent shall ensure that a the discussions could disclose
2. Reprod Biol Endocrinol 1:125, 2003. plan for supervision of Respondent’s confidential trade secrets or commercial
Retraction in: Reprod Biol Endocrinol duties is submitted to ORI for approval; property such as patentable material,
13:25, 2015 Apr 3. the supervision plan must be designed
3. J Clin Endocrinol Metab 88(3):1350–1361, and personal information concerning
to ensure the scientific integrity of individuals associated with the grant
2003. Retraction in: J Clin Endocrinol
Metab 100(1):318, 2015 Jan.
Respondent’s research contribution; applications, the disclosure of which
4. Hum Reprod 21(10):2555–2563, 2006. Respondent agreed that he shall not would constitute a clearly unwarranted
Retraction in: Hum Reprod 30(1):249, participate in any PHS-supported invasion of personal privacy.
2015 Jan (Epub 2014 Nov 6). research until such a supervision plan is
Name of Committee: National Institute of
5. Mol Hum Reprod 12(4):245–256, 2006. submitted to and approved by ORI; Allergy and Infectious Diseases Special
Retraction in: Mol Hum Reprod Respondent agreed to maintain Emphasis Panel NIAID Clinical Trial
20(12):1258, 2014 Dec (Epub 2014 Nov responsibility for compliance with the Implementation Grant (R01).
13). agreed upon supervision plan; Date: August 28, 2017.
6. Mol Hum Reprod 13(11):797–806, 2007.
(2) Respondent agreed that for a Time: 12:00 p.m. to 2:00 p.m.
Retraction in: Mol Hum Reprod
period of five (5) years beginning on the Agenda: To review and evaluate grant
20(12):1259, 2014 Dec (Epub 2014 Nov
applications.
13). date on which the Respondent receives
Place: National Institutes of Health, 5601
7. Reprod Sci 15(10):993–1001, 2007. or applies for PHS support, any Fishers Lane, Rockville, MD 20892
Retraction in: Reprod Sci 21(10):1326, institution employing him shall submit, (Telephone Conference Call).
2014 Oct. in conjunction with each application for Contact Person: Kelly Y. Poe, Ph.D.,
8. J Cell Mol Med 12(1):227–240, 2008. PHS funds, or report, manuscript, or Scientific Review Program, Division of
Retraction in: J Cell Mol Med
abstract involving PHS-supported Extramural Activities, Room 3F40B National
19(10):2512, 2015 Oct.
research in which Respondent is Institutes of Health, NIAID, 5601 Fishers
ORI found that Respondent engaged involved, a certification to ORI that the Lane, MSC 9823, Bethesda, MD 20892–9823,
in research misconduct by intentionally, data provided by Respondent are based (240) 669–5036, poeky@mail.nih.gov.
knowingly, or recklessly falsifying data on actual experiments or are otherwise (Catalogue of Federal Domestic Assistance
that were included in: J Reprod legitimately derived and that the data, Program Nos. 93.855, Allergy, Immunology,
Immunol 73(2):118–29, 2007 (hereafter and Transplantation Research; 93.856,
procedures, and methodology are
referred to as ‘‘JRI 2007’’). Specifically, Microbiology and Infectious Diseases
accurately reported in the application, Research, National Institutes of Health, HHS)
ORI found that Respondent falsified report, manuscript, or abstract;
data points and standard errors of the Dated: July 28, 2017.
(3) to exclude himself voluntarily
mean in bar graphs plotting matrix Natasha M. Copeland,
from serving in any advisory capacity to
metalloprotease expression or activity in Program Analyst, Office of Federal Advisory
PHS including, but not limited to,
the following figures of JRI 2007: Committee Policy.
service on any PHS advisory committee,
• Figures 2A, 2B, 2C board, and/or peer review committee, or [FR Doc. 2017–16314 Filed 8–2–17; 8:45 am]
• Figures 3A, 3B, 3C as a consultant for a period of five (5) BILLING CODE 4140–01–P
• Figure 4B years, beginning with the effective date
• Figure 5C of the Agreement; and
• Figure 6B DEPARTMENT OF HEALTH AND
• Figures 7A, 7B, 7C (4) as a condition of the Agreement, HUMAN SERVICES
• Figure 8, middle left panel and lower Respondent will request that J Reprod
right panel Immunol 73(2):118–29, 2007 be National Institutes of Health
retracted.
Dr. Chegini entered into a Voluntary National Institute of Allergy and
Settlement Agreement with ORI, in FOR FURTHER INFORMATION CONTACT: Infectious Diseases; Notice of Closed
which he voluntarily agreed to the Director, Office of Research Integrity,
mstockstill on DSK30JT082PROD with NOTICES

Meeting
following, beginning on July 12, 2017: 1101 Wootton Parkway, Suite 750,
(1) Respondent has not applied for or Rockville, MD 20852, (240) 453–8200. Pursuant to section 10(d) of the
engaged in U.S. Public Health Service Federal Advisory Committee Act, as
(PHS)-supported research since 2012; Kathryn M. Partin, amended, notice is hereby given of the
Respondent has no intention of Director, Office of Research Integrity. following meeting.
applying for or engaging in PHS- [FR Doc. 2017–16311 Filed 8–2–17; 8:45 am] The meeting will be closed to the
supported research or otherwise BILLING CODE 4150–31–P public in accordance with the

VerDate Sep<11>2014 16:35 Aug 02, 2017 Jkt 241001 PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 E:\FR\FM\03AUN1.SGM 03AUN1

Document Created: 2017-08-03 07:25:13
Document Modified: 2017-08-03 07:25:13

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		August 28, 2017.
FR Citation		82 FR 36151

82 FR 36151 - National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 82, Issue 148 (August 3, 2017)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health